Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients

Bibliography

• MADDREY WC: Hepatitis B: an important public health issue. J. Med. Virol. (2000) 61:362-366.
   PubMed Web of Science ®Google Scholar
• LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of hepatitis B: 2000. Summary of a workshop. Gastroenterology (2001) 120:1828-1853.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ: New developments in the treatment of chronic hepatitis B. Expert Opin. Biol. Ther. (2006) 6:913-921.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, HADZIYANNIS SJ: Current management of chronic hepatitis B. Aliment. Pharmacol. Ther. (2004) 19:25-37.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2005) 352:2673-2681.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, LAU GK, BONINO F et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2004) 351:1206-1217.
   PubMed Web of Science ®Google Scholar
• KEEFE EB, DIETERICH DT, HAN SH et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. (2006) 4:936-962.
   PubMed Web of Science ®Google Scholar
• EASL International consensus conference on hepatitis Br. J. Hepatol. (2003) 39(Suppl. 1):S3-S25.
   Google Scholar
• LAU GKK, PIRATVISUTH T, LUO KX et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2005) 352:2682-2695.
   PubMed Web of Science ®Google Scholar
• CHANG TT, GISH R, DE MAN R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2006) 354:1001-1010.
   PubMed Web of Science ®Google Scholar
• HOOFNAGLE JH: Hepatitis B – preventable and now treatable. N. Engl. J. Med. (2006) 354:1074-1076.
   PubMed Web of Science ®Google Scholar
• LAI CL, GANE E, LIAW YF et al.: Telbivudine (LDT) versus lamivudine for chronic hepatitis B: first-year results from the international Phase III GLOBE trial. Hepatology (2005) 42:748A (Abstract).
   Google Scholar
• LOK AS: The maze of treatment of hepatitis B. N. Engl. J. Med. (2005) 353:2743-2746.
   PubMed Web of Science ®Google Scholar
• LAI C-L, SHOUVAL D, LOK ASF et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2006) 354:1011-1020.
   PubMed Web of Science ®Google Scholar
• LAI CL, GANE E, HSU CW et al.: Two-years results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) versus lamivudine. Hepatology (2006) 44:222A.
   Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, CHANG TT et al.: Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology (2006) 42:754A.
   Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 131(6):1743-1751.
   PubMed Web of Science ®Google Scholar
• LAMPERTICO P, VIGANO M, MANENTI E et al.: Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 421:414-419.
   Google Scholar
• LAMPERTICO P, VIGANO M, IAVARONE M et al.: Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years. Hepatology (2006) 44:556A.
   Web of Science ®Google Scholar
• RAPTI IN, DIMOU E, MITSOULA P, HADZIYANNIS S: Combination of adefovir dipivoxil with lamivudine versus adefovir alone in lamivudine-resistant HBeAg-negative chronic hepatitis B patients. Hepatology (2007) 45:307-313.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G: Natural history and prognosis of hepatitis B. Semin. Liver Dis. (2003) 23:47-58.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ: Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev. (1995) 1:7-36.
   Google Scholar
• MCMAHON BJ: The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. (2004) 24(Suppl. 1):17-21.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV: Hepatitis Be antigen-negative chronic hepatitis B: natural history and treatment. Semin. Liver Dis. (2006) 26:130-141.
   PubMed Web of Science ®Google Scholar
• LOK AS, MCMAHON BJ: Chronic hepatitis B: update of recommendations. Hepatology (2004) 39:857-861.
   PubMed Web of Science ®Google Scholar
• CHAN HL, LEUNG NW, HUSSAIN M, WONG ML, LOK AS: Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology (2000) 31:763-768.
   PubMed Web of Science ®Google Scholar
• BRUNETTO MR, OLIVERI F, ROCCA G et al.: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology (1989) 10:198-202.
   PubMed Web of Science ®Google Scholar
• FUNK ML, ROSENBERG DM, LOK AS: World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. (2002) 9:52-61.
   PubMed Web of Science ®Google Scholar
• ZARSKI JP, MARCELLIN P, LEROY V et al.: Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J. Hepatol. (2006) 45:355-360.
   PubMed Web of Science ®Google Scholar
• MANESIS EK: HBeAg-negative chronic hepatitis B: from obscurity to prominence. J. Hepatol. (2006) 45:343-346.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, VASSILOPOULOS D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 34:617-624.
   PubMed Web of Science ®Google Scholar
• LIAW Y-F, SHEEN I-S, CHEN T-J, CHU C-M, PAO C-C: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology (1991) 13:627-631.
   PubMed Web of Science ®Google Scholar
• DE FRANCHIS R, MEUCCI G, VECCHI M et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med. (1993) 118:191-194.
   PubMed Web of Science ®Google Scholar
• VILLENEUVE J-P, DESCROCHERS M, INFANTE-RIVARD C et al.: A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology (1994) 106:1000-1005.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS S, GERBER MA, VISSOULIS C, POPPER H: Cytoplasmic hepatitis B antigen inground-glass hepatocytes of carriers. Arch. Pathol. (1973) 96:327-330.
   PubMedGoogle Scholar
• FONG T-L, DI BISCEGLIE AM, GERBER MA, WAGGONER JG, HOOFNAGLE JH: Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology (1993) 18:1313-1318.
   PubMed Web of Science ®Google Scholar
• LIAW YF, TSAI SL, SHEEN IS et al.: Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am. J. Gastroenterol. (1998) 93:354-359.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV: Emerging treatments in chronic hepatitis B. Expert Opin. Emerg. Drugs (2004) 9(2):207-221.
   PubMedGoogle Scholar
• SHAW T, LOCARNINI S: Entecavir for the treatment of chronic hepatitis B. Expert Rev. Anti Infect. Ther. (2004) 2:853-871.
   PubMedGoogle Scholar
• LEUNG N: Lamivudine for chronic hepatitis B. Expert Rev. Anti Infect. Ther. (2004) 2:173-80
   PubMedGoogle Scholar
• HAN SH: Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs (2005) 14(4):511-519.
   PubMed Web of Science ®Google Scholar
• BRUNETTO MR, OLIVERI F, COCO B et al.: Outcome of anti-HBe positive chronic hepatitis B in α-interferon treated and untreated patients: a long-term cohort study. J. Hepatol. (2002) 36:263-270.
   PubMed Web of Science ®Google Scholar
• MANESIS E, PAPATHEODORIDIS GV, SEVASTIANOS V, CHOLONGITAS E, PAPAIOANNOU C, HADZIYANNIS SJ: Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol. (2003) 98:2261-2267.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, BONINO F, LAU GK et al.: The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon α-2a (40 KD) (pegasys) sustain responses 2 years post-treatment. J. Hepatol. (2006) 44(2):S274 (Abstract).
   Google Scholar
• HADZIYANNIS S, LAU GKK, MARCELLIN P et al.: Sustaiened HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon- alfa-2a (40KD) (pegasys). J. Hepatol. (2005) 42(2):S178 (Abstract).
   Google Scholar
• BONINO F, MARCELLIN P, LAU GK et al.: Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut (2006) 56(5):699-705.
   PubMed Web of Science ®Google Scholar
• TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B eantigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology (1999) 29:889-896.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPAIOANNOU C: Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology (2000) 32:847-851.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPADIMITROPOULOS V, HADZIYANNIS SJ: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology (2002) 36:219-226.
   PubMed Web of Science ®Google Scholar
• GAIA S, MARZANO A, SMEDILE A et al.: Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. (2004) 20:281-287.
   PubMed Web of Science ®Google Scholar
• DI MARCO V, MARZANO A, LAMPERTICO P et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 40:883-891.
   PubMed Web of Science ®Google Scholar
• FUNG SK, WONG F, HUSSAIN M, LOK AS: Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J. Viral Hepat. (2004) 11:432-438.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 124:105-117.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS AS, MITSOULA P, HADZIYANNIS E et al.: Monitoring serum HBV-DNA levels with the TaqMan technique during treatment of HBeAg(-) chronic hepatitis B with lamivudine. Hepatology (2005) 1(Suppl.):726A-727A (Abstract).
   Google Scholar
• LOCARNINI S, QI X, ARTERBURN S et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J. Hepatol. (2005) 42(Suppl. 2):17.
   Web of Science ®Google Scholar
• QI X, SNOW A, THIBAULT V et al.: Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. J. Hepatol. (2004) 40(Suppl. 1):20.
   Web of Science ®Google Scholar
• YANG H, QI X, DAS K et al.: In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase. J. Hepatol. (2004) 40(Suppl. 1):114.
   Web of Science ®Google Scholar
• COLONNO RJ, ROSE RE, BALDICK CJ et al.:. High barrier of resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J. Hepatol. (2006) 44:S182.
   Web of Science ®Google Scholar
• COLONNO RJ, ROSE RE, POKORNOWSKI K et al.:. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology (2006) 44:229A.
   Google Scholar
• THONGSAWAT S, LAI CL, GANE G et al.: Telbivudine displays consistent antiviral fficacy across patient subgroups for the treatment of chronic hepatitis B: results from the GLOBE study. J. Hepatol. (2006) 44:S49.
   PubMed Web of Science ®Google Scholar
• WESTLAND CE, YANG H, NAMIMI H et al.: Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology (2001) 34:446A.
   Google Scholar
• LEE CK, YEON JE, HONG SP et al.: More frequent and earlier emergence of adefovir (ADV) resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleoside-treatment naive patients. Hepatology (2005) 42(Suppl. 1):593A.
   Web of Science ®Google Scholar
• FUNG SK, CHAE HB, FONTANA RJ et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. (2006) 44:283-290.
   PubMed Web of Science ®Google Scholar
• FUNG SK, ANDREONE P, HAN SH et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. (2005) 43:937-943.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, DIMOU E, DIMAKOPOULOS K et al.: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology (2005) 42:121-129.
   PubMed Web of Science ®Google Scholar
• CHANG TT, GISH RG, HADZIYANNIS SJ et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 129:1198-1209.
   PubMed Web of Science ®Google Scholar
• HANN WH, CHAE HB, DUM SR et al.: Tenofovir (TNV) has stronger antiviral effect than adefovir dipovoxil (ADV) against lamivudine (LAM) resistant hepatitis B virus (HBV). J. Hepatol. (2006) 44(2):S184 (Abstract).
   Web of Science ®Google Scholar